Chiome Bioscience Inc.

9 patents currently held · Updated Nov 14, 2026

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Ending by 2030

May 2031

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Dec 23, 2026
The maintenance fee for Anti-Human TROP-2 Antibody Having Anti-Tumor Activity in Vivo (US 9,062,100) comes due Dec 23, 2026. Unpaid by Jun 23, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 9 of 9

Patent	Title	Status	Expires	Confidence
US 9,062,100	Anti-Human TROP-2 Antibody Having Anti-Tumor Activity in Vivo In force Term ends May 17, 2031 · High confidence	In force	Term ends May 17, 2031	High confidence
US 9,670,287	Anti-Human TROP-2 Antibody Having Anti-Tumor Activity in Vivo In force Term ends May 17, 2031 · High confidence	In force	Term ends May 17, 2031	High confidence
US 9,427,464	Anti-Human TROP-2 Antibody Having an Antitumor Activity in Vivo In force Term ends Nov 20, 2032 · High confidence	In force	Term ends Nov 20, 2032	High confidence
US 10,202,461	Anti-Human TROP-2 Antibody Having an Antitumor Activity in Vivo In force Term ends Nov 26, 2032 · High confidence	In force	Term ends Nov 26, 2032	High confidence
US 9,879,075	Anti-semaphorin 3A antibody and treatment of Alzheimer's disease and inflammatory immune diseases using same In force Term ends Feb 6, 2034 · From the USPTO record	In force	Term ends Feb 6, 2034	From the USPTO record
US 10,941,207	Fusion Protein Comprising Three Binding Domains to 5T4 and CD3 In force Term ends Apr 20, 2037 · High confidence	In force	Term ends Apr 20, 2037	High confidence
US 11,008,566	Method for obtaining antibody In force Term ends Jul 29, 2038 · From the USPTO record	In force	Term ends Jul 29, 2038	From the USPTO record
US 11,572,402	Method for promoting diversification of antibody variable region In force Term ends Jul 15, 2039 · From the USPTO record	In force	Term ends Jul 15, 2039	From the USPTO record
US 12,680,195	Method for Promoting Diversification of Antibody Variable Region In force Ends no later than Jun 22, 2040 · Low confidence	In force	Ends no later than Jun 22, 2040	Low confidence

Also on record, not counted in the 9: 1 lapsed for an unpaid fee · 4 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

4 pending · 5 no status recorded

List them